No Data
Pfizer Sticks to 2025 Profit View as It Shrugs off Plunging Paxlovid Sales for COVID
BofA Securities Adjusts Price Target on Pfizer to $27 From $26, Maintains Neutral Rating
UBS Adjusts Price Target on Pfizer to $25 From $24, Maintains Neutral Rating
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $24 to $32
Daily short sale tracking: Amcor's short volume increased by 49 million, with a short sale ratio of 39%
Pfizer First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag
Demon Town : The market for short selling is about to open, the tariffs are delayed, and the Institutions can’t wait any longer.